Impact of an Intensified Thromboprofylaxis Protocol in COVID-19
Impact of Implementation of an Intensified Thromboprofylaxis Protocol in in Critically Ill ICU Patients With COVID-19: a Longitudinal Controlled Before-after Study
調査の概要
詳細な説明
Background Patients admitted to the Intensive Care Unit (ICU) are known to be at risk for thrombo-embolic events. Virchow's triad describes the major risk factors in three categories: venous stasis, vessel injury and activation of blood coagulation. A prolonged mechanical ventilation together with the hemodynamic effects of this ventilation with a high positive and expiratory pressure (PEEP), the presence of central venous catheters, the immobilization of these patients and the presence of obesity or other comorbidities can attribute to the occurrence of a deep venous thrombosis (DVT) in patients admitted at ICU. The incidence of DVT during ICU stay has been reported between 5 and 15%.
On the 13th of March, the first COVID-19 patient was admitted at the ICU at the Jessa Hospital. Within a few days, the admissions at our COVID-19 unit grew exponential. In these difficult time, research concerning COVID-19 has been performed indicating the COVID-19 virus induces a hyper-inflammatory state. It has been suggested that systemic inflammation induces endothelial injury. This will activate the coagulation cascade and impair fibrinolysis with disruption of endothelial barrier, and loss of physiologic antithrombotic factors which may elevated the risk for DVTs significantly. Up to now, there is still no causal treatment for COVID-19. The current management of COVID-19 is mainly supportive i.e. a prolonged inflammatory status and a prolonged risk for VTE.
We have shown in a previous cross sectional study that the prevalence of deep venous thrombosis (DVT) in critically ill ICU patients with COVID-19 treated with a prophylactic dose of low molecular weight heparin (LMWH) is more than 60% (submitted manuscript). Consequently, the risk of VTE complications in this patient group is very high. In the light of these findings, an intensified thromboprofylaxis protocol was applied in critically ill ICU patients with COVID-19 at our ICU units since 31st of March 2020.
Aim The aim of this study is to investigate and compare the mortality, the incidence of DVT and the incidence of kidney and liver failure in patients admitted to the ICU before and after the implementation of an intensified thromboprofylaxis protocol on 31st of March 2020. Patients in the before group are admitted at the ICU from 13/3/2020-30/3/2020 and patients in the after group are admitted to the ICU from 31/3 until 20/4/2020.
Design This is a retrospective, longitudinal, before-after controlled study investigating the mortality, the incidence of DVT and the incidence of kidney and liver failure in COVID-19 patients admitted to the ICU before and after the implementation of an intensified thromboprofylaxis protocol.
Outcome measures The primary endpoint of this retrospective study is to investigate the mortality in critically ill ICU patients before and after the implementation of the intensified thromboprofylaxis protocol in our hospital.
Secondary endpoints are the incidence of DVTs with the number and locations of these thromboses, the incidence of kidney failure and the incidence of liver failure in COVID-19 patients admitted to the ICU before and after the implementation of the thromboprofylaxis protocol.
Additional data collection
Additional collected parameters are listed below and are collected as a standard-of-care in our hospital:
- Demographics: i.e age, gender, BMI, Apache II score (to predict mortality)
- Comorbidities: smoking, obesity, hypertension, diabetes, cardiovascular disease, respiratory disease, malignancies, renal failure (AKI), liver failure, gastrointestinal disease, neurological conditions, mental state, other
- Symptoms at the time of admission to ICU: i.e fever, body temperature, dyspnoea, headache, diarrhea etc…
- Laboratory results of all standard parameters measured
- Treatment: antiviral agents, antibiotics, etc…
- Complications: shock, heart failure, sepsis, stroke, etc…
- Ventilation: method, PEEP, FiO2, P/F ratio ..
- SOFA score (Sequential Organ Failure Assessment)
- Radiological findings: pneumonia, ground-glass opacity..
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Hasselt、ベルギー、3500
- Jessa Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- All adult COVID19+ patients admitted to the ICU from 13th of March until 20th of April 2020.
Exclusion Criteria:
- Patients younger than 18 years old.
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Before or control group
All patients admitted to ICU from March 13th 2020 until March 30th 2020 received routine low dose pharmacological VTE prophylaxis
|
This protocol contains a routine low dose pharmacological venous thromboembolism (VTE) prophylaxis with LMWH
|
|
After or intervention group
On March 31th 2020 an individualised, more aggressive thromboprophylaxis protocol was implemented.
This individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity
|
This individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
2 week mortality
時間枠:2 weeks after admission at ICU
|
mortality was assessed in all COVID 19 patients admitted to the ICU
|
2 weeks after admission at ICU
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
incidence of venous thromboembolism
時間枠:during ICU stay up till 3th of May 2020
|
the incidence of venous thromboembolism was evaluated in all COVID 19 patients admitted to the ICU
|
during ICU stay up till 3th of May 2020
|
|
1 week mortality
時間枠:1 week after admission at ICU
|
mortality was assessed in all COVID 19 patients admitted to the ICU
|
1 week after admission at ICU
|
|
3 week mortality
時間枠:3 weeks after admission at ICU
|
mortality was assessed in all COVID 19 patients admitted to the ICU
|
3 weeks after admission at ICU
|
|
1 month mortality
時間枠:1 month after admission at ICU
|
mortality was assessed in all COVID 19 patients admitted to the ICU
|
1 month after admission at ICU
|
|
incidence of kidney failure
時間枠:during ICU stay up till 3th of May 2020
|
incidence of acute kidney failure in all COVID 19 patients admitted to the ICU
|
during ICU stay up till 3th of May 2020
|
|
incidence of continuous renal replacement therapy (CRRT)
時間枠:during ICU stay up till 3th of May 2020
|
incidence of continuous renal replacement therapy (CRRT) in all COVID 19 patients admitted to the ICU
|
during ICU stay up till 3th of May 2020
|
|
lowest PaO2/FiO2 (P/F) ratio
時間枠:during ICU stay up till 3th of May 2020
|
evaluation of the lowest P/F ratio in all COVID 19 patients admitted to the ICU
|
during ICU stay up till 3th of May 2020
|
|
highest Sequential Organ Failure Assessment (SOFA) score
時間枠:during ICU stay up till 3th of May 2020
|
evaluation of the highest SOFA score in all COVID 19 patients admitted to the ICU
|
during ICU stay up till 3th of May 2020
|
|
length of stay
時間枠:during ICU and hospital stay up till 3th of May 2020
|
evaluation of the length of stay in ICU and hospital of all COVID 19 patients admitted to the ICU
|
during ICU and hospital stay up till 3th of May 2020
|
|
highest bilirubin
時間枠:during ICU stay up till 3th of May 2020
|
evaluation of the highest bilirubine level in all COVID 19 patients admitted to the ICU
|
during ICU stay up till 3th of May 2020
|
|
highest ( AST
時間枠:during ICU stay up till 3th of May 2020
|
evaluation of the highest AST level in all COVID 19 patients admitted to the ICU
|
during ICU stay up till 3th of May 2020
|
|
highest Aspartaat-Amino-Transferase (ALT)
時間枠:during ICU stay up till 3th of May 2020
|
evaluation of the highest ALT level in all COVID 19 patients admitted to the ICU
|
during ICU stay up till 3th of May 2020
|
協力者と研究者
スポンサー
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- Jessa_20.48
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。